Antimicrobial resistance is a growing global crisis. From multidrug-resistant bacteria to treatment-resistant viruses and fungi, traditional monotherapies are losing ground.
Combination therapies are emerging as one of the most effective tools to restore efficacy, harness synergistic effects, and slow the development of resistance in infectious disease treatment — particularly in cases where standard antibiotic treatment is no longer effective, including applications informed by in vivo drug combination screening.
This article explores how drug combinations are being applied in pathogen research, how strategic screening reveals powerful synergies, and how these approaches progress into clinical studies for validation.
The Rise of Drug Resistance
Pathogens evolve rapidly. Through genetic mutation, horizontal gene transfer, and selective pressure, the development of resistance to once-effective therapies — a trend extensively documented in epidemiological reports and observational studies, and targeted clinical studies.
Key resistance mechanisms include:
- Enzyme-mediated drug inactivation
Bacteria produce enzymes such as beta-lactamases that degrade antibiotics before they reach their targets. Extended-spectrum beta-lactamases (ESBLs) and carbapenemases, especially prevalent in Gram-negative bacteria, have rendered many frontline antibiotic treatments ineffective and represent one of the most clinically significant mechanisms of resistance in hospital-based studies.
- Efflux pump overexpression
Efflux transporters eject antimicrobial agents from the cell before they can exert their effects. This is common in Gram-negative bacteria and contributes to multidrug resistance, a pattern consistently noted in hospital-based observational studies.
- Target site modification
Genetic mutations alter the structure of antibiotic targets, preventing binding. For example, MRSA modifies its penicillin-binding proteins, and fluoroquinolone resistance often arises from mutations in DNA gyrase.
- Biofilm formation or dormancy
Many pathogens enter a biofilm state or metabolic dormancy, rendering them tolerant to treatment and often requiring combination therapy to achieve effective clearance. Biofilms on catheters, implants, or tissues can be 1,000× more drug-resistant than planktonic cells, often requiring combination therapy to achieve clearance.
These adaptations drive antimicrobial resistance by reducing the efficacy of antibiotics, antivirals, and antifungals, contributing to persistent bacterial infections, bloodstream infections, severe infections, and increased mortality.
Why Combination Strategies Work
By hitting multiple targets simultaneously, combination therapy can:
- Overwhelm microbial defense mechanisms
By attacking multiple cellular functions (e.g., DNA replication + protein synthesis), combination therapy can induce lethal stress beyond the pathogen’s adaptive capacity, overcoming defense systems that typically neutralize antimicrobial agents.
- Prevent escape via redundancy or pathway blockade
In combination therapy, dual inhibition of converging or compensatory pathways (e.g., folate biosynthesis + membrane disruption) reduces the probability of resistance emergence.
- Reduce required doses and minimize toxicity
In combination therapy, when two drugs act synergistically, their synergistic effects allow each to be dosed below its toxic threshold, lowering the risk of adverse effects and preserving host microbiota or tissue health — while still delivering a potent attack with antimicrobial agents.
- Delay resistance development
The probability of a pathogen acquiring simultaneous resistance to two or more drugs is orders of magnitude lower than for one agent—making combination therapy an essential tool in antimicrobial resistance management and in delaying the emergence of resistance.
Synergistic combination therapy regimens enhance efficacy while delaying the onset of resistance — a critical advancements over traditional antibiotic therapy in managing bacterial infections, severe infections, and improving global health outcomes, as demonstrated in recent observational studies.
Screening Drug Combinations for Pathogens
Effective screening is essential for identifying potent drug pairings that can form the basis of advanced combination therapy approaches, As resistance mechanisms become more complex, combination therapy screening plays a critical role in prioritizing regimens that warrant further evaluation in observational studies and clinical settings. Common approaches include:
- Checkerboard assays for pairwise dose matrix evaluation
This gold-standard format for identifying high-potential combination therapy regimens, across a 2D matrix of concentrations, enabling synergy quantification via fractional inhibitory concentration (FIC) indices.
- Time-kill curves to assess dynamic effects
They are essential for determining how combination therapy impacts microbial killing over time. Measuring bacterial or fungal load over time reveals whether a combination accelerates or sustains microbial killing — a vital consideration when optimizing antibiotic therapy and improving the overall effectiveness of antibiotic treatment for resistant infections.
- Phenotypic assays for cellular or morphological change
These are critical in identifying which compounds work best together in combination therapy. Microscopy, flow cytometry, and high-content imaging detect changes in morphology, membrane integrity, or intracellular accumulation—indicating compound mechanism.
- Host-pathogen co-culture models to simulate infection context
It helps predict how combination therapy will perform in realistic biological systems. Including immune cells or tissue-like structures (e.g., lung epithelial cells, gut organoids, or vascular models for bloodstream infections) allows evaluation of compound effects within a realistic biological system, including scenarios that mimic the inflammatory and vascular changes seen in septic shock.
Custom screening must consider the biology of the target pathogen (bacteria, virus, fungus) — including resistance-prone groups like Gram-negative bacteria — to ensure that combination therapy regimens are both targeted and effective. Additionally, it should also consider the mode of action of the drugs, especially when addressing critical conditions like bloodstream infections or combating antimicrobial resistance.
Scoring Synergy in Infectious Models
Once data is collected, drug synergy models help quantify interaction effects:
- Bliss Independence
Assumes each drug acts independently. Used when mechanisms are unrelated. Positive deviation from expected effects indicates synergy and supports the potential for combination therapy using clinical settings.
- Loewe Additivity
Appropriate when drugs share or overlap mechanisms. Loewe scores help identify whether lower doses in combination therapy outperform their single-agent treatnent.
- ZIP (Zero Interaction Potency)
A surface modeling approach that visualizes synergy across the full dose matrix. ZIP provides a landscape of interaction intensity, highlighting optimal dosing regions.
- HSA (Highest Single Agent)
Benchmarks the combination effect against the more potent monotherapy. It’s a conservative model useful for initial prioritization.
Antagonism detection is equally critical to avoid harmful interactions that reduce efficacy or increase resistance risk.
Use Cases & Clinical Successes
Combination therapy is already the standard of care in several infectious diseases, demonstrating its proven ability to reduce resistance and improve patient outcomes:
- HIV
Highly active antiretroviral therapy (HAART) is a proven form of combination therapy, using three or more drugs targeting different stages of the viral life cycle. This approach dramatically reduces viral load and resistance emergence, with long-term benefits supported by large-scale observational studies in diverse patient populations.
- Tuberculosis (TB)
A four-drug combination therapy regimen (isoniazid, rifampicin, pyrazinamide, ethambutol) is standard for TB treatment. It prevents resistance and ensures clearance across different bacterial subpopulations.
- MRSA and Gram-negative bacterial infections, including bloodstream infections
Combining beta-lactams with beta-lactamase inhibitors (e.g., piperacillin/tazobactam) restores antibiotic susceptibility and strengthens antibiotic therapy by neutralizing resistance enzymes. This is particularly critical for the treatment of infections caused by Acinetobacter baumannii, a Gram-negative bacteria notorious for multidrug resistance and frequent involvement in hospital-acquired infections. In severe cases — especially when infections progress to septic shock, where rapid initiation of effective combination therapy can be lifesaving.
- Fungal infections
This antifungal combination therapy in Candida auris and invasive aspergillosis, azoles combined with echinocandins improve outcomes by targeting membrane and cell wall biosynthesis concurrently.
These examples highlight the importance of preclinical synergy screening to inform effective clinical regimens.
Designing Screens to Match Pathogen Biology
To maximize insight, screening must reflect real infection environments:
- Stress conditions
Simulating in vivo factors such as acidic pH (e.g., stomach, phagolysosomes), hypoxia (e.g., granulomas), or high protein binding (e.g., serum exposure) affects compound activity and pathogen behavior.
- Use of clinical isolates or resistant strains
Reference strains may not capture the diversity or resistance profiles seen in patients. Including resistant clinical isolates ensures relevance to current antibiotic therapy challenges and helps identify effective drug combinations for real-world infections, enabling smoother translation to observational studies and eventual clinical trials.
- Co-cultures with immune cells or tissue analogs
These systems model host-pathogen interactions and allow researchers to measure drug effects on both pathogen killing and immune modulation.
- Phenotypic outputs
Measuring real cellular outcomes—such as lysis, adhesion, or invasion—provides insight into whether the combination translates into functional clearance.
Phenotypic outputs help detect subtle synergy and predict clinical translatability.
How Kyinno Supports Infectious Disease Screening
Kyinno offers end-to-end support for combination screening programs targeting infectious diseases. Our platform is designed for speed, flexibility, and actionable insights.
Our capabilities include:
- Custom microbial panels and resistance libraries. We work with Gram-positive, Gram-negative, bacteria, fungal, and viral models—including MDR and XDR strains commonly implicated in bloodstream infections, tailored to your target geography or indication.
- Dose matrix design and execution. Our team develops optimized checkerboard or fixed-ratio matrices to capture synergy without wasting compounds or data resolution.
- Synergy scoring using Bliss, Loewe, ZIP, and HSA. Our analytics pipeline supports all major scoring models with visualization outputs, enabling clearer interpretation and lead prioritization.
- AI-supported prediction and hit ranking. We integrate past assay data and public datasets with machine learning tools to rank combinations by predicted efficacy, resistance suppression, and translational potential.
We deliver fast, reliable data to help global health researchers respond to resistance threats with clarity and speed.
Conclusion
Antimicrobial resistance demands innovation. While conventional antibiotic therapy continues to lose ground, combination therapy—supported by strategic screening and validated through targeted observational studies—offers a powerful countermeasure against rising threats like bloodstream infections and septic shock.
→ Partner with Kyinno to execute drug combination screening services for infectious disease combo studies that advance both science and public health. Book a consultation today.